RAHWAY, N.J.--(BUSINESS WIRE) August 8, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the...

The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or...

CAMBRIDGE, Mass., Aug. 13, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in...

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Tryptamine...

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU...

HANGZHOU, China, Aug. 15, 2024. Vimgreen Pharmaceuticals, a science-driven pharmaceutical company focused on the modulation of adenosine signaling,...

Indian Council of Medical Research (ICMR) and Panacea Biotec declared the start of Phase III clinical trial for India's first dengue vaccine.

BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...